Data from RCTs involving kidney transplant recipients will be needed to provide a clearer pro le of the true risks and bene ts of a SPRINT-like goal in this population. Similar to the non-transplant CKD population (Recom- mendation 1.2), ABPM or HBPM may be used to comple- ment standardized of ce BP readings for the diagnosis and management of high BP in the kidney transplant population. As with the general population, classi cation of BP status using out-of-of ce BP is often different from classi cation using standardized of ce BP in kidney transplant recipients; the complementary use of out-of-of ce BP measurements may lead to more appropriate therapeutic decisions.303,304 Again, it should be noted that there have been no completed RCTs targeting different BP values using either of ce BP readings or out-of-of ce BP readings in the kidney transplant population. Recommendation 4.1: We recommend that a dihy- dropyridine calcium channel blocker (CCB) or an ARB be used as the rst-line antihypertensive agent in adult kidney transplant recipients (1C). This recommendation places a relatively higher value on pre- venting kidney allograft loss and a relatively lower value on the risk of a possible medication-related side effect. This recom- mendation is strong because in the judgment of the Work Group, the potential prevention of transplant failure outweighs potential risks of burden associated with its implementation. The Work Group also judged that all or nearly all well-informed transplant patients would choose to receive a CCB or an ARB given the potential bene t. Key information Balance of bene ts and harms. 